

#### **HB-EGF**

Catalog # PVGS1687

### **Specification**

#### **HB-EGF - Product Information**

Primary Accession Species Seriola XP\_023257950.1

Sequence

Ser88-Leu179

**Purity** 

≥ 90% as analyzed by SDS-PAGE

**Endotoxin Level** 

< 0.2 EU/  $\mu g$  of protein by gel clotting method

**Biological Activity** 

ED<SUB>50</SUB> < 1.0  $\mu$ g/ml, measured by a cell proliferation assay using BALB/3T3 cells, corresponding to a specific activity of > 1.0  $\times$  10<sup>3</sup> units/mg.

**Expression System** 

<I>E.coli</I>

**Theoretical Molecular Weight** 

10.06 kDa

Formulation

Lyophilized from a 0.2 µm filtered solution in 50 mM Tris, 150 mM Nacl, pH 8.0

#### Reconstitution

Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>0 up to 100  $\mu$ g/ml

# **Storage & Stability**

Upon receiving, this product remains stable up to 6 months at -20  $^{\circ}$ C or below. Upon reconstitution, the product should be stable up to 1 week at 4  $^{\circ}$ C or up to 3 months at -20  $^{\circ}$ C. Avoid repeated freeze-thaw cycles.

### **HB-EGF - Additional Information**

# **Target Background**

HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic and chemotactic glycoprotein. An epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It has been shown to play a role in wound healing, cardiac hypertrophy, and heart development and function.

### **HB-EGF - Protein Information**



Tel: 858.875.1900 Fax: 858.875.1999



# **HB-EGF - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

**HB-EGF - Images**